Celltrion
068270.KS
$150.87
Share price
1.74%
Change (1 day)
-14.38%
Change (1 year)
Categories
Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.
Revenue for Celltrion (068270.KS)
Revenue in 2024 (TTM): S$3.44 Billion
According to Celltrion
's latest financial reports the company's current revenue (TTM 
) is S$3.39 Billion. an increase over the revenue in the year 2023 that were of S$2.17 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Celltrion from 2008 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | S$3.50 B | 60.93% |
| 2023 | S$2.17 B | -7.3% |
| 2022 | S$2.35 B | 5.6% |
| 2021 | S$2.22 B | 5.72% |
| 2020 | S$2.10 B | 61.04% |
| 2019 | S$1.30 B | 7.18% |
| 2018 | S$1.21 B | 7.2% |
| 2017 | S$1.13 B | 35.16% |
| 2016 | S$0.84 B | 13.66% |
| 2015 | S$0.74 B | 24.75% |
| 2014 | S$0.59 B | 126.42% |
| 2013 | S$0.26 B | -33.23% |
| 2012 | S$0.39 B | |
| 2010 | S$0.20 B | 23.5% |
| 2009 | S$0.16 B | 58.9% |
| 2008 | S$0.10 B |